Efinopegdutide
Also called MK-6024, HM12525A
Subcutaneous (under the skin)Human study reference
Research reference
Human study
Efinopegdutide liver-fat phase 2a trial
Once weekly: 2.4 mg for 4 weeks → 5 mg for 4 weeks → 10 mg through week 24
24 weeks, including 8 weeks of escalation
Efinopegdutide phase 2a methods (2023) ↗When results may show
- When change was measured
- MRI liver-fat change was measured at week 24; this was not a trial proving reversal of liver scarring.
- When to assess
- 24 weeks, including 8 weeks of escalation
- Conditions and limitations
- 145 adults with fatty liver; MRI liver fat at least 10%. Condition-specific study-product schedule, not a general weight-loss or personal vial plan.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
Published research contexts for Efinopegdutide describe 5–10 mg per administration. Descriptive only, not a recommendation.
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.57× single dose
- Time to steady state
- 25.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Efinopegdutide phase 2a methods (2023)Condition-specific study-product schedule, not a general weight-loss or personal vial plan.
Next steps
Efinopegdutide beginner guideOpen Efinopegdutide planning worksheetEstimate Efinopegdutide vial costTrack Efinopegdutide notes